Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes

被引:0
|
作者
Sherman S. Leung
Nataliya Lenchik
Clayton Mathews
Alberto Pugliese
Domenica A. McCarthy
Selena Le Bagge
Adam Ewing
Mark Harris
Kristen J. Radford
Danielle J. Borg
Ivan Gerling
Josephine M. Forbes
机构
[1] The University of Queensland (MRI-UQ),Glycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI)
[2] The University of Queensland,Faculty of Medicine
[3] Griffith University,School of Medicine and Dentistry
[4] Wesley Research Institute,Division of Endocrinology, Department of Medicine
[5] The Wesley Hospital,Division of Endocrinology, Department of Microbiology and Immunology, Department of Medicine, Diabetes Research Institute, Miller School of Medicine
[6] University of Tennessee Health Science Center,Translational Bioinformatics Group
[7] University of Miami,Queensland Diabetes Centre
[8] MRI-UQ,Cancer Immunotherapies Group
[9] TRI,undefined
[10] Mater Health Services,undefined
[11] MRI-UQ,undefined
[12] TRI,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hypoglycemia in type 1 diabetes associates with changes in the pancreatic islet α cells, where the receptor for advanced glycation end products (RAGE) is highly expressed. This study compared islet RAGE expression in donors without diabetes, those at risk of, and those with type 1 diabetes. Laser-dissected islets were subject to RNA bioinformatics and adjacent pancreatic tissue were assessed by confocal microscopy. We found that islets from type 1 diabetes donors had differential expression of the RAGE gene (AGER) and its correlated genes, based on glucagon expression. Random forest machine learning revealed that AGER was the most important predictor for islet glucagon levels. Conversely, a generalized linear model identified that glucagon expression could be predicted by expression of RAGE signaling molecules, its ligands and enzymes that create or clear RAGE ligands. Confocal imaging co-localized RAGE, its ligands and signaling molecules to the α cells. Half of the type 1 diabetes cohort comprised of adolescents and a patient with history of hypoglycemia—all showed an inverse relationship between glucagon and RAGE. These data confirm an association between glucagon and islet RAGE, its ligands and signaling pathways in type 1 diabetes, which warrants functional investigation into a role for RAGE in hypoglycemia.
引用
收藏
相关论文
共 50 条
  • [31] Advanced glycation end products and endothelial dysfunction in type 2 diabetes
    Tan, KCB
    Chow, WS
    Ai, VHG
    Metz, C
    Bucala, R
    Lam, KSL
    DIABETES CARE, 2002, 25 (06) : 1055 - 1059
  • [32] The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha
    Lohwasser, Christina
    Neureiter, Daniel
    Weigle, Bernd
    Kirchner, Thomas
    Schuppan, Detlef
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (02) : 291 - 299
  • [33] Advanced Glycation End Products, Soluble Receptor for Advanced Glycation End Products, and Risk of Colorectal Cancer
    Jiao, Li
    Taylor, Philip R.
    Weinstein, Stephanie J.
    Graubard, Barry I.
    Virtamo, Jarmo
    Albanes, Demetrius
    Stolzenberg-Solomon, Rachael Z.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (07) : 1430 - 1438
  • [34] ATORVASTATIN INDUCES THE EXPRESSION OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS
    Tam, X.
    Shiu, S.
    Chow, W. S.
    Wong, Y.
    Betteridge, J.
    Tan, K.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [35] Developmental expression and regulation of receptor for advanced glycation end products (RAGE)
    Reynolds, Paul R.
    Huecksteadt, Tom P.
    Sturrock, Anne
    Hoidal, John R.
    DEVELOPMENTAL BIOLOGY, 2006, 295 (01) : 379 - 379
  • [36] Soluble Receptor for Advanced Glycation End-Products (sRAGE) as an Early Serum Marker of Preeclampsia in Type 1 Diabetes
    Yu, Yongxin
    Hanssen, Kristian F.
    Kalyanaraman, Venkataraman
    Wilson, Kenneth W.
    Chirindel, Alin
    Jenkins, Alicia J.
    Nankervis, Alison J.
    Torjesen, Peter
    Scholz, Hanne
    Henriksen, Tore
    Lorentzen, Bjorg
    Clausen, Torun
    Garg, Satish K.
    Menard, M. Kathryn
    Hammad, Samar M.
    Scardo, James C.
    Stanley, John R.
    Dashti, Azar
    May, Kerri
    Aston, Christopher E.
    Lyons, Timothy J.
    DIABETES, 2009, 58 : A470 - A470
  • [37] Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes
    Lee, Alan C. H.
    Lam, Joanne K. Y.
    Shiu, Sammy W. M.
    Wong, Ying
    Betteridge, D. John
    Tan, Kathryn C. B.
    PLOS ONE, 2015, 10 (09):
  • [38] Advanced glycation end products, diabetes and ageing
    Nass, N.
    Bartling, B.
    Santos, A. Navarrete
    Scheubel, R. J.
    Boergermann, J.
    Silber, R. E.
    Simm, A.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2007, 40 (05): : 349 - 356
  • [39] Advanced glycation end products, diabetes, and the brain
    Coker, Laura H.
    Wagenknecht, Lynne E.
    NEUROLOGY, 2011, 77 (14) : 1326 - 1327
  • [40] Advanced glycation end products, dementia, and diabetes
    Lovestone, Simon
    Smith, Ulf
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (13) : 4743 - 4744